We found that down-regulation of SMAD5 and TGF-βR2 was associated with increased expression of miR-155 in CD34+ cells from CML patients compared to healthy controls (Figure 2A, B)(Fig. 2). The gene discussed is SMAD5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.